Perrigo bounces back: stock up 19.2% in first quarter -- Index.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO STOCK RECOVERS FROM YEAR-END HIT WITH 19.2% FIRST QUARTER GROWTH after closing 1996 with a 23.2% drop. Investors may be reacting to the OTC private labeler's earnings upturn after several years of declines. In mid-February, Perrigo reported second quarter sales ahead 10% on earnings growth of 12.6%. A severe cough, cold and flu season drove Perrigo's largest OTC segments -- cough/cold remedies and analgesics
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.